Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
H. Lundbeck A/S
Participants will be randomly allocated to one of 3 treatment groups: Lu AG09222 high dose, Lu AG09222 low dose, or placebo, in a ratio of 2:1:2.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The participant has a diagnosis of migraine as defined by International Classification of Headache Disorders Third Edition (ICHD-3) guidelines confirmed at the Screening Visit.
The participant has a history of migraine onset at least 12 months prior to the Screening Visit.
The participant has a migraine onset at ≤50 years of age.
The participant has documented evidence of treatment failure in the past 10 years of at least 2 to 4 (maximum) different migraine preventive medications.
You may not be if
The participant has been previously dosed with an anti-pituitary adenylate cyclase-activating polypeptide (anti-PACAP) ligand-targeting antibody.
The participant has confounding and clinically significant pain syndromes.
The participant has a diagnosis of acute or active temporomandibular disorder.
The participant has a history or diagnosis of confounding headaches.
Clareo Health | A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
